Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease.
Ontology highlight
ABSTRACT: Solid tumors frequently metastasize to bone and induce bone destruction leading to severe pain, fractures, and other skeletal-related events (SREs). Osteoclast inhibitors such as bisphosphonates delay SREs but do not prevent skeletal complications or improve overall survival. Because bisphosphonates can cause adverse side effects and are contraindicated for some patients, we sought an alternative therapy to reduce tumor-associated bone destruction. Our previous studies identified the transcription factor Gli2 as a key regulator of parathyroid hormone-related protein (PTHrP), which is produced by bone metastatic tumor cells to promote osteoclast-mediated bone destruction. In this study, we tested the treatment effect of a Gli antagonist GANT58, which inhibits Gli2 nuclear translocation and
SUBMITTER: Vanderburgh JP
PROVIDER: S-EPMC7007697 | biostudies-literature | 2019 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA